(lp0
S'Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading ... GlobeNewswire  - Jul 22, 2016 FORT WASHINGTON, Pa., July 22, 2016  -- Madrigal Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the&nbsp;...'
p1
aS"Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License ... GlobeNewswire  - Sep 19, 2016 CONSHOHOCKEN, Pa. and WATERTOWN, Mass., Sept. 19, 2016  -- Madrigal Pharmaceuticals, Inc.  and Tarveda Therapeutics, Inc. today announced an exclusive worldwide license agreement providing for the&nbsp;...With $163M Deal, Tarveda Revives Synta Pharma's Cancer Drug Work - XconomyTarveda to Develop Oncology Treatments Based on Madrigal's HSP90 Drug ... - Genetic Engineering & Biotechnology News "
p2
aS'Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL ... GlobeNewswire  - Feb 23, 2017 CONSHOHOCKEN, Pa., Feb. 23, 2017  -- Madrigal Pharmaceuticals, Inc.  today announced that the first patient has been dosed in its Phase 2 study of MGL-3196 for the treatment of heterozygous familial&nbsp;...'
p3
aS'Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL ... GlobeNewswire  - Oct 20, 2016 CONSHOHOCKEN, Pa., Oct. 20, 2016  -- Madrigal Pharmaceuticals, Inc.  today announced that the first patient has been dosed in its Phase 2 study of MGL-3196 for the treatment of non-alcoholic steatohepatitis .'
p4
aS'Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals Zacks.com - Apr 15, 2016 This all-stock transaction will lead to the formation of a new company named Madrigal Pharmaceuticals, which will focus on the development of novel small-molecule drugs addressing major unmet needs related to cardiovascular-metabolic diseases and&nbsp;...Synta Pharma and Madrigal Pharma to merge in all-stock deal - Seeking AlphaSynta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular ... - Business Wire '
p5
aS'Madrigal Pharmaceuticals  EPS Estimated At $0.00, Profile of 0 Analysts ... Herald KS - 18 hours ago Analysts expect Madrigal Pharmaceuticals Inc  to report $0.00 EPS on March, 21. The stock decreased 1.63% or $0.26 on March 17, reaching $15.74.'
p6
aS'Breaking: Madrigal Pharmaceuticals Inc  Stock Through Resistance ... CML News - Mar 16, 2017 Breaking: Madrigal Pharmaceuticals Inc  has hit maximum technical strength -- watch the technical oscillators for momentum gaps.'
p7
aS'BRIEF-Paul A. Friedman, MD reports 8.25 pct stake in Madrigal Pharmaceuticals Reuters - Aug 1, 2016 ... * Paul A. Friedman, M.D. reports 8.25 pct stake in Madrigal Pharmaceuticals as of July 22, 2016 - SEC Filing Source - bit.'
p8
aS'Synta - Madrigal Merger: Is There A Potential Value Play Here? Seeking Alpha - Aug 23, 2016 On April 13, 2016 Synta and Madrigal Pharmaceuticals  entered into an arrangement and plan of merger pursuant to which Saffron Merger Sub Inc., a wholly owned subsidiary of Synta, will merge into MDGL, with Madrigal surviving as the&nbsp;...'
p9
aS'A New Kind of Stock Chart: Madrigal Pharmaceuticals Inc  Critical ... CML News - Feb 27, 2017 This is a real time view of the critical technical pivot points for Madrigal Pharmaceuticals Inc  . The technical pivot points we look at all surround the stock price movement from the last 10-trading days through the last year.'
p10
a.